AR091013A1 - Agonistas de los receptores v1a - Google Patents

Agonistas de los receptores v1a

Info

Publication number
AR091013A1
AR091013A1 ARP130101626A AR091013A1 AR 091013 A1 AR091013 A1 AR 091013A1 AR P130101626 A ARP130101626 A AR P130101626A AR 091013 A1 AR091013 A1 AR 091013A1
Authority
AR
Argentina
Prior art keywords
compounds
agonists
receiver agonists
receiver
vasopressin
Prior art date
Application number
Other languages
English (en)
Inventor
Felix Galyean Robert
S Harris Geoffrey
Wisniewski Kazimierz
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR091013A1 publication Critical patent/AR091013A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

Se describen los compuestos de la fórmula (1), las sales de la misma, y las composiciones y usos de los mismos. Los compuestos son útiles como agonistas V1a (receptor de vasopresina) de la vasopresina para el tratamiento de, por ejemplo, complicaciones de la cirrosis, que incluyen peritonitis bacteriana, HRS2 (síndrome hepatorrenal tipo II) y ascitis refractaria.
ARP130101626 2012-05-10 2013-05-10 Agonistas de los receptores v1a AR091013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261645558P 2012-05-10 2012-05-10

Publications (1)

Publication Number Publication Date
AR091013A1 true AR091013A1 (es) 2014-12-30

Family

ID=48652296

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101626 AR091013A1 (es) 2012-05-10 2013-05-10 Agonistas de los receptores v1a

Country Status (29)

Country Link
US (1) US9644000B2 (es)
EP (1) EP2847210B1 (es)
JP (1) JP6231554B2 (es)
KR (1) KR102050356B1 (es)
CN (1) CN104350065B (es)
AR (1) AR091013A1 (es)
AU (1) AU2013259393B2 (es)
BR (1) BR112014027996B1 (es)
CA (1) CA2871776C (es)
DK (1) DK2847210T3 (es)
ES (1) ES2571928T3 (es)
HK (1) HK1205706A1 (es)
HR (1) HRP20160468T1 (es)
HU (1) HUE027519T2 (es)
IL (1) IL235558A (es)
JO (1) JO3109B1 (es)
MX (1) MX353864B (es)
MY (1) MY167248A (es)
NZ (1) NZ701365A (es)
PH (1) PH12014502510B1 (es)
PL (1) PL2847210T3 (es)
RS (1) RS54722B1 (es)
RU (1) RU2634617C2 (es)
SA (1) SA113340536B1 (es)
SG (1) SG11201407400XA (es)
SI (1) SI2847210T1 (es)
TW (1) TWI632161B (es)
WO (1) WO2013170077A2 (es)
ZA (1) ZA201408172B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388214B2 (en) 2014-11-05 2016-07-12 Ferring B.V. V1A receptor agonists
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス,インコーポレイテッド 腹水の治療
RS63143B1 (sr) 2016-06-01 2022-05-31 Athira Pharma Inc Jedinjenja
CN109010795B (zh) * 2018-09-12 2021-10-22 南京康舟医药科技有限公司 醋酸特利加压素注射液以及其制备方法
MX2023000737A (es) * 2020-07-17 2023-02-13 Pharmain Corp Agonista parcial del receptor de vasopresina subtipo v1a y metodo de uso.
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
WO2024073451A1 (en) * 2022-09-30 2024-04-04 Ocelot Bio, Inc. Mixed vasopressin receptor agonist-antagonist for treating end-stage liver disease and complications associated thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU32702A (sh) * 1999-11-04 2005-06-10 Ortho-Mcneil Pharmaceutical Inc. Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
BRPI0612988A2 (pt) * 2005-07-14 2010-12-14 Hoffmann La Roche derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a
CA2623715A1 (en) * 2005-09-28 2007-04-12 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
EP1984012B1 (en) * 2006-02-13 2015-12-30 Ferring B.V. Use of peptidic vasopressin receptor agonists
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs

Also Published As

Publication number Publication date
CN104350065A (zh) 2015-02-11
CA2871776A1 (en) 2013-11-14
JP2015518820A (ja) 2015-07-06
IL235558A0 (en) 2015-01-29
RS54722B1 (en) 2016-08-31
HUE027519T2 (en) 2016-10-28
RU2634617C2 (ru) 2017-11-02
CA2871776C (en) 2021-09-07
SG11201407400XA (en) 2014-12-30
ZA201408172B (en) 2015-12-23
US9644000B2 (en) 2017-05-09
WO2013170077A2 (en) 2013-11-14
HRP20160468T1 (hr) 2016-06-03
SI2847210T1 (sl) 2016-06-30
RU2014143941A (ru) 2016-07-10
JP6231554B2 (ja) 2017-11-15
BR112014027996A2 (pt) 2017-07-25
AU2013259393A1 (en) 2014-11-20
KR102050356B1 (ko) 2019-11-29
KR20150008175A (ko) 2015-01-21
HK1205706A1 (zh) 2015-12-24
US20150126432A1 (en) 2015-05-07
JO3109B1 (ar) 2017-09-20
IL235558A (en) 2017-07-31
DK2847210T3 (en) 2016-05-02
PH12014502510A1 (en) 2014-12-22
MX2014013646A (es) 2015-03-03
BR112014027996B1 (pt) 2021-07-27
EP2847210B1 (en) 2016-02-17
WO2013170077A3 (en) 2014-03-27
NZ701365A (en) 2016-05-27
MY167248A (en) 2018-08-14
ES2571928T3 (es) 2016-05-27
MX353864B (es) 2018-02-01
CN104350065B (zh) 2020-04-28
TW201348262A (zh) 2013-12-01
SA113340536B1 (ar) 2015-10-08
PH12014502510B1 (en) 2014-12-22
EP2847210A2 (en) 2015-03-18
TWI632161B (zh) 2018-08-11
AU2013259393B2 (en) 2017-02-02
PL2847210T3 (pl) 2016-08-31

Similar Documents

Publication Publication Date Title
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
AR091013A1 (es) Agonistas de los receptores v1a
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO7400867A2 (es) Modificador del sabor dulce
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
UY34591A (es) Compuestos de imidazopirrolidinona
UY34765A (es) Compuestos novedosos.
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
UY34649A (es) Compuestos heterobicíclicos
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
EA201491305A1 (ru) Конденсированные трициклические соединения в качестве ингибиторов raf киназы
ECSP11011206A (es) Nuevos herbicidas.
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
UY34251A (es) derivados de isoxazolina como compuestos insecticidas.
ECSP11011485A (es) Espiro-epóxidos como productos intermedios.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
UY34469A (es) Composicion herbicida

Legal Events

Date Code Title Description
FG Grant, registration